PMID- 35847922
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220719
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Postoperative Concurrent Chemoradiotherapy for Locally Advanced Thoracic 
      Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial.
PG  - 900443
LID - 10.3389/fonc.2022.900443 [doi]
LID - 900443
AB  - BACKGROUND: This study aims to investigate the efficacy and safety of 
      postoperative intensity-modulated radiotherapy (IMRT) covering partial regional 
      lymph node areas combined with chemotherapy for locally advanced thoracic 
      esophageal squamous cell carcinoma patients. METHODS: This was a single-center, 
      single-arm phase II clinical trial that began in 2014. Patients who underwent 
      radical transthoracic resection within 3 months and were histologically confirmed 
      esophageal squamous cell carcinoma (pT3-4 or N+, M0 determined according to AJCC 
      Guidelines, Edition 7) were recruited. Postoperative radiotherapy was performed 
      with a total dose of 50.4Gy in 28 fractions using IMRT. Clinical target volumes 
      (CTVs) included tumor bed, anastomosis, bilateral supraclavicular region, and 
      superior mediastinal lymph nodes. Synchronous chemotherapy for 2 cycles 
      (paclitaxel 150mg/m(2), day1; Cisplatin 25mg/m(2), day1-3; every 4 weeks), 
      followed by 2 cycles of consolidation chemotherapy with the same regimen. The 
      primary endpoint was the 2-year local control rate, and the secondary endpoints 
      were overall survival (OS) and adverse events (AEs). RESULTS: A total of 75 
      eligible patients were included from 2014 to 2017. The 2-year LRFS rate, as the 
      primary endpoint, was 73.3%. The 1-year and 3-year OS rates were 88.0% and 68.0%, 
      respectively. Local recurrence occurred in 13/75 (17.4%) patients, of which 2.7% 
      (2/75) were extra-target lymph nodes. Grade 4 adverse events reported in this 
      study included 10 cases (13.3%) of neutropenia, 1 case (1.3%) of anemia, and 2 
      cases (2.7%) of thrombocytopenia, without toxic-related deaths. Almost all (96%) 
      patients completed the entire postoperative radiotherapy course, and 62 (82.7%) 
      patients completed at least 2 cycles of chemotherapy. CONCLUSION: Postoperative 
      IMRT (clinical target volume including tumor bed, anastomosis, bilateral 
      supraclavicular region, and superior mediastinal lymph nodes) combined with 
      synchronous chemotherapy in patients with locally advanced thoracic esophageal 
      squamous cell carcinoma was well tolerated, with a high local control rate and a 
      low probability of recurrence outside the irradiation field. CLINICAL TRIAL 
      REGISTRATION: https://clinicaltrials.gov/ChiCTR1900022689.
CI  - Copyright (c) 2022 Li, Gu, Du, Zhou, Zhang and Ye.
FAU - Li, Hui
AU  - Li H
AD  - Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
FAU - Gu, Dayong
AU  - Gu D
AD  - Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
FAU - Du, Mingyu
AU  - Du M
AD  - Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
FAU - Zhou, Guoren
AU  - Zhou G
AD  - Department of Oncology, Affiliated Cancer Hospital of Nanjing Medical University, 
      Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
FAU - Zhang, Zhi
AU  - Zhang Z
AD  - Department of Thoracic Surgery, Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
FAU - Ye, Jinjun
AU  - Ye J
AD  - Department of Radiation Oncology, Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20220630
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9280634
OTO - NOTNLM
OT  - CTVs
OT  - IMRT
OT  - cover partial regional lymph node areas
OT  - esophageal squamous cell carcinoma
OT  - postoperative treatment
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/19 06:00
MHDA- 2022/07/19 06:01
PMCR- 2022/01/01
CRDT- 2022/07/18 04:22
PHST- 2022/03/20 00:00 [received]
PHST- 2022/06/01 00:00 [accepted]
PHST- 2022/07/18 04:22 [entrez]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/07/19 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.900443 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jun 30;12:900443. doi: 10.3389/fonc.2022.900443. eCollection 
      2022.